Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
ascopubs.org

Utilization of Systemic Therapy in Patients With Cancer Near the End of Life in the Pre- Versus Postimmune Checkpoint Inhibitor Eras

Expanded Access and Right To Try Requests: The Community Oncologist's Experience We hypothesized that because of availability of ICIs, systemic therapy use in the last 30 days of life (DOL) would have ...
The American Journal of Managed Care

Systemic Therapy in BCC

Morgana Freeman, MD: The use of hedgehog inhibitors really relies on our understanding of how basal cell carcinoma [BCC] uniquely grows. Basal cell carcinoma relies on something called the smoothened ...
Medscape

Radiotherapy Defers Systemic Therapy in Oligometastatic RCC

Serial metastasis-directed radiotherapy extended time off systemic therapy while maintaining favorable progression-free and overall survival in patients with oligometastatic clear-cell renal cell ...
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Breaking News: Trump administration impacts continue to roil the life sciences sector Home » Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo ...
BioWorld

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy, named WFX-001, being developed for the treatment of Fabry disease.